Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation.

Expert review of hematology - 1 Sept 2026

Benevolo Giulia, Lanzarone Giuseppe, Rosti Benedetta, Beggiato Eloise

Abstract excerpt

INTRODUCTION: Myelofibrosis (MF) is a heterogeneous myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, cytopenias, and risk of leukemic transformation. As therapeutic options expand, treatment discontinuation and sequencing are increasingly recognized as clinically relevant determinants of patient outcomes. AREAS COVERED: A literature search was performed using PubMed/MEDLINE and...

Read the complete abstract on PubMed

Topics

Humans
Primary Myelofibrosis
Mutation
Janus Kinase Inhibitors
Treatment Interruption

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 42441864
DOI: 10.1080/17474086.2026.2688872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation.PMID 42441864Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment AdvancementsSemantic proximity Read ↗

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsSemantic proximity Read ↗

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and managementSemantic proximity Read ↗

Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.Semantic proximity Read ↗

How I treat myelofibrosis after failure of JAK inhibitors.Semantic proximity Read ↗

Molecular profile of patients with myelofibrosis: a 10-year experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.